Not FDA-approved1,2,4Evidence: Smaller human trialsInflammation and immune · Cancer · Infections

Thymosin alpha-11

Also called Thymalfasin1

Key takeaway

Thymosin alpha-1 (Ta1, also called thymalfasin) is a 28-amino-acid peptide first isolated from calf thymus in 1977. It is not an FDA-approved drug, although FDA notes that a product containing it is licensed in other countries.1 In 2024 FDA staff reviewed its use in 12 conditions, including hepatitis B and C, HIV, sepsis and several cancers, and found a lack of evidence of effectiveness for any of them.1 FDA’s advisory committee voted 17 to 4 against adding it to the list of substances pharmacies may use in compounding. Thymosin alpha-1 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,6

Thymosin alpha-1 at a glance

What it isA 28-amino-acid peptide with an acetylated N-terminus, originally isolated from a thymus extract; FDA describes thymalfasin as a chemically synthesized version.1
FDA statusNot FDA-approved. FDA’s 2024 evaluation states that it is not a component of an FDA-approved drug, and FDA lists it among compounding substances that may present significant safety risks.1,4
Human evidenceMany clinical studies, mostly small, including randomized trials in sepsis and melanoma, which FDA found inconclusive and limited by design problems.1
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is thymosin alpha-1?

Thymosin alpha-1 is a 28-amino-acid peptide, acetylated at one end, that was first isolated in 1977 from thymosin fraction 5, a crude extract of calf thymus, according to FDA’s evaluation.1

FDA states that thymalfasin is a chemically synthesized version of Ta1, and that Zadaxin is a finished product containing it that is available in other countries but is not interchangeable with the bulk substance.1

How is thymosin alpha-1 thought to work?

FDA’s evaluation describes immune-modulating effects attributed to activation of Toll-like receptors on dendritic cells and immune precursor cells, which are thought to explain effects against tumors, sepsis and viruses in laboratory and animal models.1

FDA notes that most of these studies used amounts far higher than those used in people, so their clinical relevance is unclear.1

What do human studies show?

In a randomized trial of 361 people with severe sepsis, 28-day death rates were 26% with Ta1 and 35% in the control group, which did not reach statistical significance; FDA notes that the trial was not double-blinded.1

Across the 12 uses it reviewed, FDA concluded that studies were inconclusive and limited by small size and design problems, such as missing control groups, lack of blinding and outdated comparison treatments.1

FDA reports that in most studies Ta1 was well tolerated, with irritation where it was given being the most common reaction, but that safety data are insufficient for some proposed uses, such as after stem cell transplants or alongside flu vaccines.1

What the evidence base contains

  • Controlled human trial A multicenter, single-blind, randomized trial (ETASS) in 361 people with severe sepsis, in which 28-day deaths were 26% with Ta1 and 35% in the control group, a difference that was not statistically significant, described in FDA’s evaluation.1
  • Controlled human trial An exploratory, open-label, randomized trial in 488 people with advanced melanoma, and small double-blind trials in hepatitis, described in FDA’s evaluation.1
  • Animal or laboratory research Laboratory and animal studies of immune effects through Toll-like receptors, which FDA found hard to relate to people because of the high amounts used.1

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is thymosin alpha-1 FDA-approved?

No. FDA’s evaluation, dated November 15, 2024, states that neither Ta1 nor its acetate salt is a component of an FDA-approved drug, and that there is no United States Pharmacopeia monograph for either.1

FDA staff evaluated both forms for the 503A bulks list, the list of substances pharmacies may use in compounding, and concluded that the balance of criteria weighs against adding them.1

A Federal Register notice announced the December 4, 2024 advisory-committee meeting that discussed thymosin alpha-1. According to the minutes, the committee voted 17 to 4 against placing each form on the list.2,3

FDA’s compounding safety-risk page, current as of April 22, 2026, lists thymosin alpha-1 among substances whose nominations were withdrawn, citing a possible significant risk of immune reactions and inadequate safety information.4

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Thymosin alpha-1 is not among them.5,6

Timeline

  1. Thymosin alpha-1 is first isolated from calf thymus, according to FDA’s evaluation.1
  2. A Federal Register notice announces the December 4, 2024 advisory-committee meeting that will discuss thymosin alpha-1.3
  3. FDA staff date their evaluation recommending against adding thymosin alpha-1 to the 503A bulks list.1
  4. FDA’s Pharmacy Compounding Advisory Committee votes 17 to 4 against placing thymosin alpha-1 on the list.2
  5. FDA’s compounding safety-risk page, as last updated, lists thymosin alpha-1 among withdrawn nominations with safety concerns.4

What is still unknown?

Whether it helps in any of the conditions FDA reviewed when added to current standard care, which FDA states is unknown because many studies used outdated treatments.1

FDA’s final decision on the 503A list, which was not part of the sources reviewed through November 15, 2026.1,4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Thymosin alpha-1: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Thymosin alpha-1 are a bounded selection, not every registration or paper about Thymosin alpha-1. For the years before Thymosin alpha-1 was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Thymosin alpha-1 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Thymosin alpha-1 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

Not FDA-approved; FDA advised against adding it to the compounding list. FDA staff recommended in 2024 against adding thymosin alpha-1 to the 503A compounding list, and FDA lists it among substances that may present significant safety risks. It is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Thymosin alpha-1?

Not FDA-approved; FDA advised against adding it to the compounding list. FDA staff recommended in 2024 against adding thymosin alpha-1 to the 503A compounding list, and FDA lists it among substances that may present significant safety risks. It is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
2
Source years
15
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Thymosin alpha-1?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

48Selected dated records
54Connected citations
15Populated source years2008–2026
2/4Record lanes present

Registered human studies

Trial composition

17 of 18 selected trial records include at least one phase value; 18 of 18 include a status value in the retained structured contract.

PhasesPhase 2 9Phase 3 3Phase 4 3Phase 1 2Not applicable 1
Status at observationCompleted 13Not yet recruiting 2Recruiting 2Active, not recruiting 1

A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”

PubMed bibliography

Publication composition

30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 30Review 18Randomized Controlled Trial 8Multicenter Study 6Research Support, Non-U.S. Gov't 6Clinical Trial 2Meta-Analysis 2Clinical Trial, Phase II 1Comparative Study 1Systematic Review 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
48

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 48 dated records

Research hub

Explore the Thymosin alpha-1 evidence record

Open all 48 records →
48Dated records
2Evidence types
48Cited public sources
15Source years

Change ledger

Recently changed for Thymosin alpha-1

Open all 48 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00001036

PeptideScanner retained ClinicalTrials.gov record NCT00001036 at 2026-11-15T22:10:40.222Z. Its registry update date was 2008-07-30, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

PeptideScanner change date
November 15, 2026
Cited source date
July 30, 2008
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00711620

PeptideScanner retained ClinicalTrials.gov record NCT00711620 at 2026-11-15T22:10:40.222Z. Its registry update date was 2011-06-14, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

PeptideScanner change date
November 15, 2026
Cited source date
June 14, 2011
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00911443

PeptideScanner retained ClinicalTrials.gov record NCT00911443 at 2026-11-15T22:10:40.222Z. Its registry update date was 2009-07-09, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

PeptideScanner change date
November 15, 2026
Cited source date
July 9, 2009
Evidence lane
Clinical trials

Official-source collections

Source records for Thymosin alpha-1

Open the full research atlas →
PubMed30

30 with attributed title, venue, publication-date, and type metadata.

  1. Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026 09 19
  2. Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial.BMC medicine · 2026 02 26
  3. Aging and Thymosin Alpha-1.International journal of molecular sciences · 2025 11 27
Explore all selected literature →
ClinicalTrials.gov18

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT07922954Registry update November 6, 2026 · current at observation
  2. NCT07884201Registry update October 20, 2026 · current at observation
  3. NCT07780721Registry update August 21, 2026 · current at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span July 30, 2008 to November 6, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2,4
  • U.S. Department of Health and Human Services5
Dated updates connected to this profile · 48

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT07922954↗

    PeptideScanner retained ClinicalTrials.gov record NCT07922954 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-11-06, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT07884201↗

    PeptideScanner retained ClinicalTrials.gov record NCT07884201 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.↗

  3. Literature metadata

    Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review.↗

    PubMed lists PMID 42797537 in Pharmaceuticals (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2026-09-19 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial.↗

    PubMed lists PMID 41749205 in BMC medicine as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2026-02-26 (day precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT07780721↗

    PeptideScanner retained ClinicalTrials.gov record NCT07780721 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT06139419↗

    PeptideScanner retained ClinicalTrials.gov record NCT06139419 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT06024356↗

    PeptideScanner retained ClinicalTrials.gov record NCT06024356 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-06-18, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT04428008↗

    PeptideScanner retained ClinicalTrials.gov record NCT04428008 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT06461910↗

    PeptideScanner retained ClinicalTrials.gov record NCT06461910 at 2026-11-15T22:10:40.222Z. Its registry update date was 2026-03-03, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.↗

  10. Literature metadata

    Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment.↗

    PubMed lists PMID 15546255 in Journal of gastroenterology and hepatology as Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Thymosin alpha 1: past clinical experience and future promise.↗

    PubMed lists PMID 20536460 in Annals of the New York Academy of Sciences as Journal Article, Review, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Thymalfasin in the treatment of hepatitis B and C.↗

    PubMed lists PMID 20536462 in Annals of the New York Academy of Sciences as Journal Article, Review, with publication-date metadata of 2010-04 (month precision). PeptideScanner associated the retained record with the identity slug thymosin-alpha-1. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    FDA evaluation of thymosin alpha-1-related bulk drug substances, November 15, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  2. 2
    December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    Federal Register notice 2024-24828 · published 2024-10-25 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗

    Federal Register via GovInfo · Official source · Source checked August 21, 2026

  4. 4
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  5. 5
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026